Arabic Arabic English English French French German German
dark

FDA CRL Hurdle for LEO Pharma on Tralokinumab

The U.S. FDA has released a Complete Response Letter (CRL) following its review of LEO Pharma’s tralokinumab. Further data on a device component is the issue brought to light by the recently completed Biologics License Application (BLA) review. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

CareCar Raises $3M to Expand Tech-enabled Benefit Manager Platform

Next Post

KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors

Related Posts
Total
0
Share